Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bourne Capital Partners through its Canadian subsidiary, Critique Pharmaceuticals has announced the acquisition of Theramed, a full-service Canadian medical device, pharmaceutical and biotech commercialization company.
Subscribe to our email newsletter
T Baugh III, managing director of Bourne Partners, has been named CEO of Theramed. Concurrent with the acquisition of Theramed, Bourne Partners has assigned its exclusive right to import, market and distribute Collatamp G in Canada to Theramed.
Collatamp G is used for local hemostasis of capillary, parenchymatous and seeping hemorrhages in areas with a high risk of infection. Bourne Partners secured the exclusive Canadian distribution rights to Collatamp G from Eusa Pharma (Europe).
Banks Bourne, senior managing director of Bourne Partners, remarked: “The combination of Theramed’s management and infrastructure with the substantial potential of Collatamp G offers dynamic growth possibilities. In addition to our current portfolio, we are aggressively pursuing business development opportunities in our areas of therapeutic focus to further Theramed’s growth.”